SABS News

SAB BIO Reports Full Year 2025 Financial Results and Business Highlights

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director

SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference

First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D

SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D

SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142